TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03466736

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]flutemetamol PET scan
Description: Each subject will receive an amyloid PET scan with \[18F\]flutemetamol

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]flutemetamol PET scan
Description: Each subject will receive an amyloid PET scan with \[18F\]flutemetamol

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]flutemetamol PET scan
Description: Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
Study: NCT01660854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous challenge
Description: challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone treatment
Description: Three days: 4 tablets 250/100mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone treatment
Description: Three days: 4 tablets 250/100mg per day
Study: NCT03216447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Tacrolimus prolonged-release hard capsules (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Tacolimus capsules (q12h)
Study: NCT01136096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention
Description: 1. An interview with a physiotherapist~2. An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~3. An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~4. The daily record to check their body weight, exercise mode and duration~5. Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~6. Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General instruction and education
Description: 1. Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~2. Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~3. Without individualized exercise program and interview with a physiotherapist
Study: NCT01296295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling and spirometry
Description: The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
Study: NCT06584370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericardial insufflation with carbon dioxide through a transatrial microcatheter
Description: Separate the walls of the pericardium by insufflating the pericardial space with carbon dioide.
Study: NCT00859937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03817112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride 0.1 MG/ML
Description: Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 MG/ML
Description: Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
Study: NCT03060954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI WELL READY ®
Description: BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY

Intervention type: DEVICE
Group type: OTHER
Intervention: FINE VISION®
Description: FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
Study: NCT00006249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT01296295

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Smoking cessation advice
Description: Brief smoking cessation advice
Study: NCT04222712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed four times a day (QID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed four times a day (QID)
Study: NCT03530579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational group trainings
Description: Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~* Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease \& Diabetes Complication Session 5: Stress Management Session 6: Access to Service

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Care Worker
Description: A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
Study: NCT00864747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride Extended Release Capsules 160 mg
Description: A: Experimental Subjects received Actavis formulated products under non-fasting conditions
Study: NCT01329939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Age-dependent dose, nightly, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Age-dependent dose, nightly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Age-dependent dose, nightly, 24 weeks
Study: NCT01383317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)
Description: Disposable sterile thigh tourniquet
Study: NCT01329939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Age-dependent dose, nightly, 24 weeks
Study: NCT00033553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/sq m IV over 30 min days 1 \& 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 3-D XRT 7400 cGy total after induction (during cycles 3-9)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 3-D XRT 7400 cGy total after induction (during cycles 3-9)
Study: NCT03364738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
Study: NCT01383317

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: Disposable sterile thigh tourniquet
Study: NCT03730987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HoMBReS intervention
Description: Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
Study: NCT03560167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventricular Restoration System
Description: AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
Study: NCT03330795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 neg allogeneic BMT
Description: Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
Study: NCT03245398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with one of the two regimens of mebendazole
Description: Once in the morning and once in the evening for 3 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with one of the two regimens of mebendazole
Description: Once in the morning and once in the evening for 3 consecutive days
Study: NCT00989963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Description: 60µg Tablets, twice a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Description: 60µg Tablets, twice a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Description: 60µg Tablets, twice a day for 12 weeks
Study: NCT00964821

Intervention type: BIOLOGICAL
Intervention: trivalent influenza vaccine
Description: Patients or normal volunteers who will be vaccinated against the flu.

Intervention type: OTHER
Intervention: Immunoenzyme technique
Description: This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.

Intervention type: OTHER
Intervention: Immunoenzyme technique
Description: This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
Study: NCT00880191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT01677858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
Study: NCT00864747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INDERAL® LA 160 mg Capsules, single dose
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
Study: NCT01024907

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy
Description: Undergo radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study
Study: NCT03730987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together (FTT)
Description: The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
Study: NCT01024907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study
Study: NCT01972737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-hGCC-PADRE vaccine
Description: A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
Study: NCT04130399

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
Study: NCT00483964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nardostachys jatamansi

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study: NCT01176227

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kyodophilus multi-strain probiotic capsules
Description: The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Kyodophilus Matching Placebo Capsules
Description: Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
Study: NCT00550095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Study: NCT01495585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Commercially approved products used to test the research hypothesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Commercially approved products used to test the research hypothesis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT03795675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Cochlear implant device to be implanted at time of surgical intervention.
Study: NCT00719004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the foot
Description: These volunteers will have one ultrasound scan of each foot
Study: NCT03730987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Intervention
Description: Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
Study: NCT01377194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study: NCT02418000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6201
Description: Single Group Assignment
Study: NCT02323854

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation
Description: Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Resection
Description: The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
Study: NCT03266120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Art
Description: Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gardening
Description: Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
Study: NCT01999595

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control TENS
Description: Control TENS was the application of electrical stimulation via skin with no current

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency TENS with large pads
Description: High frequency TENS was delivered on large electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency TENS with large pads
Description: Low frequency TENS was delivered on large electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency TENS with small pads
Description: High frequency TENS was delivered on small electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency TENS with small pads
Description: Low frequency TENS was delivered on small electrodes
Study: NCT03462238

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection for Ppi assay
Description: A 4.5 ml blood sample will be taken with a citrate vacuum tube.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection for Ppi assay
Description: A 4.5 ml blood sample will be taken with a citrate vacuum tube.

Intervention type: RADIATION
Group type: OTHER
Intervention: CT Scan
Description: A scanner will be performed
Study: NCT02780544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin-to-skin contact
Description: skin-to-skin contact with parent during eye examination.
Study: NCT03462238

Intervention type: RADIATION
Group type: OTHER
Intervention: CT Scan
Description: A scanner will be performed
Study: NCT00177892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep disruption
Description: experimentally-induced Sleep Fragmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep disruption
Description: experimentally-induced Sleep Fragmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleep disruption
Description: experimentally-induced Sleep Fragmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep with and without positive pressure
Description: OSAH patients with and without chronic positive airway pressure therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep with and without positive pressure
Description: OSAH patients with and without chronic positive airway pressure therapy
Study: NCT01883427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo containing saline+glucose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose oxidase
Description: a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
Study: NCT03920631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microtransplantation
Description: HLA-mismatched peripheral blood stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microtransplantation
Description: HLA-mismatched peripheral blood stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microtransplantation
Description: HLA-mismatched peripheral blood stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microtransplantation
Description: HLA-mismatched peripheral blood stem cells